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Abstract: Much has occurred since our 2010 report in Cancers. In the past few years we 
published several extensive reviews of our research so a brief review is all that will be 
provided here. We proposed in the earlier reports that most relapses in breast cancer occur 
within 5 years of surgery and seem to be associated with some unspecified manner of 
surgery-induced metastatic initiation. These events can be identified in relapse data and are 
correlated with clinical data. In the last few years an unexpected mechanism has become 
apparent.  Retrospective  analysis  of  relapse  events  by  a  Brussels  anesthesiology  group 
reported that a perioperative NSAID analgesic seems to reduce early relapses five-fold. We 
then proposed that primary surgery produces a transient period of systemic inflammation. 
This has now been identified by inflammatory markers in serum post mastectomy. That 
could explain the early relapses. It is possible that an inexpensive and non-toxic NSAID 
can reduce breast cancer relapses significantly. We want to take this opportunity to discuss 
database  quality  issues  and  our  relapse  hazard  data  in  some  detail.  We  also  present  a 
demonstration that the computer simulation can be calibrated with Adjuvant-on-line, an 
often used clinical tool for prognosis in breast cancer. 
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1. Introductory Comments on Quality of Breast Cancer Databases 
Researchers who study relapse rates in breast cancer are aware that breast cancer databases often 
have accuracy problems especially after the first few years of follow-up. There are many reasons for 
this.   
The disease runs its course in over 15 years [1,2]. In that time, patients move and modify treatments, 
data base managers die, retire or change jobs, physicians die or retire, computer systems fail or are 
changed—just to name the obvious reasons. In Italy patients are known to be generally compliant with 
physician directives and move infrequently, so few patients there are lost to follow-up. The Milan data 
have been under the personal control of P. Valagussa, who looked after databases from important 
randomized  clinical  trials  (e.g.,  the  seminal  trial  on  adjuvant  CMF  for  node-positive  early  breast 
cancer) since the first patients were treated decades ago [3]. Valagussa is a no-nonsense person and 
very diligent. She was doing the data management and would be the first person to discover a problem 
and she would take action immediately. She does not have a PhD or is a physician but she has spoken 
on breast cancer to an audience of several thousand medical oncologists and clearly knows much about 
the disease. Her data are universally considered reputable and our experience substantiates that. We 
analyzed  the  Milan  data,  consisting  of  1173  patients  undergoing  mastectomy  without  any  other 
adjuvant treatment, with high confidence of their quality and accuracy. 
In particular, it should be emphasized that in this database the time of recurrence was determined 
with high accuracy. Indeed, the proper determination of the time to event is a basic requisite to avoid 
biases in uncovering the shape of hazard rate curve. In the Milan database, for each patient the time to 
recurrence was discussed by the clinical team: when recurrence was not detected due to symptoms 
inducing the patient to anticipate the planned clinical control (about 80% of cases), a review of both 
clinical and instrumental data was performed. 
This is not a trivial matter. To put quality of breast cancer databases in perspective, we can describe 
some real problems that we personally have encountered regarding such databases. One of us (MR) 
was Visiting Professor in Department of Medical Oncology at University of Texas Health Science 
Center—San Antonio (UTHSC-SA) in 1989. This was in the department of the late William McGuire 
who was an early recognizer of the importance of estrogen and progesterone receptors in breast cancer 
[4]. MR’s project was to add estrogen receptor to a previously developed computer simulation using 
the   
San Antonio data base. This was a very large database consisting of medical records and frozen tissue 
and  serum  from  57,000  breast  cancer  patients.  Access  was  provided  to  a  Cray  supercomputer  in 
Austin, TX for this project. The UTHSC-SA staff did not want to provide a full copy of the entire 
database to a visiting scientist so a few key columns were downloaded and given to MR. The first step 
was to make sure the existing simulation was consistent with these data. We had technical problems 
making the simulation run on the supercomputer but with some effort these were eventually solved. Cancers 2014, 6  3 
 
 
Running the Cray with thousands of cases took several hours of CPU time. A serious problem occurred 
however when we determined that the existing simulation that worked relatively accurately with our 
own data with 2%–3% error was producing an unacceptable 10%–20% error with the UT data. This 
was a very complicated hardware/software procedure and changing computer systems especially was a 
focus  of  our  investigation.  We  examined  and  reexamined  everything  and  could  not  find  anything 
wrong. The problem remained. A few months later we discovered that the columns given to us were 
mislabeled. Instead of what we thought was date of relapse, we were actually given date of last office 
visit. With the proper labeling we got nearly our expected accuracy but too much time had elapsed to 
do  the  simulation   
of estrogen. 
While the investigation of why the errors were so high was underway, we got a backdoor look into 
the UTHSC-SA data management process. With such a large database to manage, about 15 young 
women sat in a row in a long lowly lit room each with a computer and telephone. They knew how 
important the project was and were intent on doing it well. We noticed a number of sticky notes on the 
wall in front of each person to remind them to contact such and such doctor’s office to get updates on 
individual patients. We also found out that these women were not highly paid. They were mostly 
spouses  of  US  Army  personnel  stationed  at  the  nearby  Ft.  Sam  Houston.  These  soldiers  were 
frequently reassigned to other bases so there was a steady turnover of women updating the UTHSC-SA 
database. It impressed us that with constant turnover of data entry personnel and management partly by 
sticky notes, it was possible for errors to slip in. The frozen tissue and fluids were stored in freezers in 
a basement and damaged by a flood in Louisiana a few years ago, but the UTHSC-SA database played 
an important and historic role in establishing HER-2/neu as a major subject in breast cancer [5]. 
Having this personal knowledge of what can go wrong even under the best of intentions in large 
database management, we appreciated the value of one competent person managing a relatively small 
database in Milan, where data were obtained by physicians performing follow-up visits and not by 
telephone. Computer simulation is mentally demanding and the researcher must have it lodged in his 
or her mind that these data are valid. You simply cannot do a good job of developing detailed and error 
free software to model human cancer growth when doubts exist of the data to be modeled. 
2. Results and Discussion 
Based  on  computer  simulation  of  the  Milan  relapse  data  in  1997  we  proposed  that  something 
happened at or about the time of surgery to initiate the early wave of relapses within 3–4 years of   
surgery [6,7]. There are other ways to represent relapse data but it is customary to measure time from 
primary surgery. This has the effect of allowing us to clearly see events that are synchronized to the 
surgical event. The early relapse hazard data in Milan data were too sharply peaked to be explained by 
any purely stochastic process. Something must have happened at surgery to synchronously kick-off 
metastatic  activity  for  a  significant  number  of  patients.  We  could  identify  clusters  of  metastatic 
relapses that we attributed to single cells that started to divide at the time of surgery and avascular 
micrometastases that underwent an angiogenic switch at the time of surgery. The latter were most 
prominent for premenopausal patients with positive lymph nodes. We had a few theories but nothing 
stood out as overly compelling. As reported in the 2010 Cancers paper [1], we could explain much Cancers 2014, 6  4 
 
 
clinical  behavior  with  the  surgery-accelerated  metastatic  growth  hypothesis.  These  include  why 
adjuvant  chemotherapy  is  most  effective  for  premenopausal  node  positive  patients  and  why 
mammography works better for women age 50–59 than it does for women age 40–49. 
Most relapses in untreated breast cancer are in the early category. The late relapses we proposed to 
be stochastically driven events that are not synchronized to surgery other than cutting off the supply of 
cancer cells shed from the primary. 
Shortly after the 2010 Cancers paper was published, a report was presented by an anesthesiology 
group from Brussels including P. Forget and M. De Kock [8]. They retrospectively reviewed the 
outcome from 327 consecutive breast cancer patients treated at their hospital. Patients were given 
mastectomy  performed  by  one  surgeon  and  this  was  followed  by  conventional  adjuvant  therapy 
according to accepted consensus reports. The relapse outcome was presented grouped by what drug 
was used as analgesia. The surprising development was that one analgesic drug resulted in 5-fold 
lower relapse hazard 9–18 months post-surgery compared to all the other drugs. The best drug was 
ketorolac which was the only NSAID out of the six in the group. 
We were perhaps primed to consider this development. In 2005 we were asked to review a case 
report  from  Lebanon  in  which  a  43  year  old  male  with  a  smoking  history  was  diagnosed  with 
inoperable stage IIIA or IIIB poorly differentiated non-small cell lung cancer [9]. The prognosis for 
this stage is very poor with 5-year survival of approximately 10%. Treatment was chemotherapy and 
radiation. While relapse was inevitable, the patient was seemingly doing well 15 months after primary 
treatment. The patient then incurred a minor trauma to the right temporal skull bone; within a month, 
the patient reported a rapidly growing 7 cm tumor at the place of the trauma. Imaging revealed tumor 
had penetrated the skull with meningeal invasion, and while some compression was apparent, it did not 
yet invade the brain (lung cancer most often relapses to the brain or adrenal glands, but can recur 
virtually anywhere, including the skeleton). The patient died 15 days later of massive hemoptysis. 
The authors suggested that it was not a coincidence that both the growth occurred at the location of 
the trauma and that the growth started shortly after the trauma. Such a phenomenon has been reported 
by others [10–12]. The mechanisms suggested include some type of trauma-induced angiogenesis of a 
dormant micrometastasis or dormant malignant cells that happened to be at that place, or perhaps, there 
were no cancer cells at the site, but circulating cancer cells were entrapped there due to the trauma. 
Being  that  we  had  a  quantitative  computer  simulation  of  breast  cancer  and  assuming  NSCLC 
growth was not too much different from breast cancer we could say with confidence that it was not 
possible that this case report showed surgery induced angiogenesis of some dormant deposit. The only 
explanation that seemed possible to us was that the minor trauma resulted in inflammation at the site of 
trauma and that circulating cancer cells were entrapped there similar to what the authors suggested. 
This was an exaggerated situation to be sure; however in our published comments we suggested that 
inflammation  can  be  a  facilitating  precursor  to  tumor  and  may  be  a  new  and  possibly  important 
hematologic metastatic pathway [13]. 
So it was not too great a leap for us to consider that, since an NSAID at the time of surgery seemed 
to prevent early relapses according to the Brussels report, this may indicate that surgery somehow 
resulted in transient systemic inflammation and the inflammation was part of the initiation process for 
early relapses. We sensed the importance of this, teamed with the anesthesiologists, and analyzed the 
situation involving perioperative NSAIDs and early relapses and concluded there are a number of Cancers 2014, 6  5 
 
 
biologically  sound  ways  by  which  the  Brussels  NSAID  intervention  prevented  transient  systemic 
inflammation following surgery and effectively blocked events leading to early relapse [14,15]. This 
could explain both the Milan data and the Brussels data. The implications are potentially important 
since this is an inexpensive and non-toxic treatment, can be done anywhere in developed or developing 
communities and could (if Brussels data will be confirmed) reduce breast cancer relapses and mortality 
by 25% to 50%. This is all discussed in our recent reviews. 
Demicheli et al. have reported similar relapse patterns in other cancers such as NSCLC and Uveal 
Melanoma [16,17]. Perhaps this is a general effect rather than applying to only a few malignancies. 
Also Forget, De Kock et al. report other breast cancer databases showing this perioperative NSAID 
effect including breast conservation surgery and they also report a simple preoperative marker that 
would be related to the systemic inflammation [18–20]. 
2.1. What Other Databases Show a Multimodal Relapse Pattern? 
There  are  several  papers  reporting  on  recurrence  or  mortality  that  explicitly  acknowledge  the 
occurrence of multiple hazard rate peaks [21–35], and other papers where such peaks may be seen   
but  are  not  explicitly  acknowledged,  although  both  the  peak  pattern  and  its  explanations  may  be   
different [36–46]. Still another paper reports gene differences between early and late relapses [47]. 
Regarding the Yakovlev et al. paper [27], the main author is now deceased and the document itself 
does not state anything about multimodal relapse but one of us (MR) spent an afternoon in New York 
with him discussing this subject. Yakovlev clearly told us that there is a bimodal relapse pattern in his 
data. 
About peak patterns, discrepancies are not surprising and may be ascribed to different database 
quality levels (as previously explained), and different details of the analysis. The discretization of time, 
for example, is crucial for detecting hazard rate structures: in our experience analyzing events in a   
3 month time lag allowed detecting the fine structure of premenopausal recurrence risk during the first 
three years (Figure 1) that was elusive in the previous 6 month analysis and that is undetectable in a   
12  month  analysis.  Moreover,  it  is  essential  to  have  a  clear  definition  of  the  analyzed  variable,   
which  should  be  unambiguous  (e.g.,  distant  metastasis,  death  for  any  cause, etc.).  In  this  regard,   
it is instructive to examine the excellent paper of Karrison et al. aimed to evaluate the limit of breast 
cancer dormancy [25]. The authors “did not see evidence for a second peak in the hazard curve”, an 
occurrence that may be ascribed to the event they analyzed (“first recurrence or death from breast 
cancer”). Indeed, while the events “first recurrence” and “death from breast cancer” reliably identify 
patients  who  are  not  cured,  the  combined  event  is  not  a  useful  end  point  for  study  of  the 
time-dependent structure of the hazard of each of the two events. This point is supported by the fact 
that when the yearly discrete hazard for time to death from all causes for breast cancer patients from 
the Karrison et al. study (1547 patients) and from the Milan study (1173 patients) were compared, both 
curves display an initial peak at about 3 to 4 years and a second peak at 8 years with an impressive 
similarity in values [48]. 
The naive evaluation of Kaplan-Mayer (KM) curves suggests the occurrence of peaks without other 
details.  Indeed,  the  confidence  on  the  occurrence  of  “true”  peaks  instead  of  artifacts  from  data 
processing relies on their constancy when: (a) different smoothing modalities are utilized (we used Cancers 2014, 6  6 
 
 
both Kernel-like smoothing and more sophisticated models such as for example flexible piecewise 
exponential  regression  models)  and  (b)  different  databases  and  different  subsets  of  patients  are 
analyzed. 
Referring to Figure 1, these patients were untreated with adjuvant therapy. Trimodal relapse pattern 
is apparent in this case whereas a bimodal pattern is usually seen for treated patient groups [15].   
The peak in hazard at 10 months from surgery is the result of surgery-induced angiogenesis of dormant 
avascular  micrometastases  according  to  the  computer  simulation.  Likewise  the  30  month  peak  is 
identified as single malignant cells that are induced into division at the time of surgery and then 
stochastically undergo angiogenesis. The broader peak at 50–60 months according to the simulation 
represents what may be called natural history relapse events and apparently are not stimulated into 
growth by surgery. The top of that peak identifies when the benefit of removing the primary tumor that 
sheds metastatic cells first appears so that may be considered temporally tied to the surgical event.   
The remaining very small hills and valleys after the 50–60 month peak are apparently noise due to very 
few events and according to the simulation are not associated with or synchronized to the time of 
surgery.  Are  the  10,  30  and  50–60  month  peaks  real  or  might  they  be  merely  an  artifact  of  the 
numerical analysis? That is a key question and reasonable to ask. We can say these peaks are routinely 
identified in our analyses, no matter what methodology is adopted, and the timing of the events is 
constant and quantitatively consistent with our model. 
Figure 1. Recurrence hazard rate for Milan premenopausal patients. 
 
Looking at Figure 2, where the same data as in the prior Figure 1 are presented in the more common 
disease free survival (DFS) format, it is clear that the plateau between 3 and 5 years represents the end 
of the early relapse events and the late relapse events are shortly to be seen. Indeed, the hazard rate is 
related to the slope of the KM curves. With this concept in mind we may look at KM curves and 
qualitatively detect presence of structured hazard rates, such as in the Fisher et al. paper (Figure 3) 
[41].  This  figure  has  been  seen  for  30  years  but  it  was  only  after  we  identified  the  multimodal 
distribution in the Milan data was it clear that Fisher et al. data also show a multimodal relapse pattern. 
Looking at the node negative curve at the top, surgery alone cures 80% of such patients. Of the 20% of 
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patients that relapse, half are in the early wave of 1–3 years post-surgery and the other half are late 
relapses greater than 5 years post-surgery. For the highest risk category at the bottom, surgery alone is 
clearly inadequate since all patients relapse and 90% of these are in the early category and 10% in the 
late category. This is visually and quantitatively what we found for the Milan data. From this figure, 
the large magnitude of the early relapses is apparent. Over half of all relapses in untreated patients are 
in the early group. Visually apparent multimodal data from another clinical group are presented in 
Figure 4. 
Figure 2. Milan data in disease-free survival format for premenopausal patients. Modified 
from Bonadonna et al. [3].   
 
Figure 3. Disease-free-survival reported (modified) from Fisher et al. [41]. Cancers 2014, 6  8 
 
 
 
   Cancers 2014, 6  9 
 
 
Figure 4. Saphner et al. data (Saphner et al. ECOG trials, Hazard of Relapse). These data 
which  combine  approximately  10  clinical  trials  for  a  variety  of  controls  and  adjuvant 
therapies clearly show bimodal hazard. The error bars are small as a result of the large 
number of patients. Modified from Saphner et al. [39]. ECOG is the Eastern Cooperative 
Oncology Group. 
 
3. Can the Simulation Be Adjusted to Match Specific Clinical Data? 
As an exercise and to demonstrate that the simulation can be adjusted to agree with clinical data,   
we  used  the  Milan  data  for  premenopausal  patients  and  examined  to  what  exact  clinical  situation   
this  corresponds.  We  used  the  often  used  and  clinically  validated  website  Adjuvant-on-line 
(http://www.adjuvantonline.com/index.jsp).  Milan  data  were  used  as  an  intermediate  connection 
between the simulation and Adjuvant. Milan data are for untreated patients. As Adjuvant provides only 
10 year disease-free-survival, it could correspond to different sets of prognostic factors. For the Milan 
premenopausal data, the corresponding Adjuvant situation could be for a patient 45 years of age, tumor 
size 2.1 to 3.0 cm, N-, ER unknown, Grading unknown. It also could be for a patient 45 years of age, 
tumor size 1.1 to 2.0, N+ 1–3, ER unknown, Grading unknown. Hazard of relapse for these data and 
simulations are shown in Figure 5 and corresponding DFS data are shown in Figure 6. 
In  Figure  5  we  are  comparing  the  Milan  data  for  premenopausal  patients  and  the  simulation.   
We adjusted the simulation to try and agree with hazard and DFS for the Milan data. The cohort that 
was  generated  using  the  simulation  consisted  of  a  linear  combination  of  patient  groups  that  were 
predisposed to relapse at approximately 10 or 30 months after surgery as a result of surgery induced 
activity plus a group that would relapse with stochastic events only. No other adjustments were made 
to produce Figures 5 and 6. This calibration exercise was conducted on a trial and error basis with 
much data traffic between US and Italy where the simulation and analysis software respectively reside. 
Initial figures were far apart and, as adjustments were made, the simulation and Milan data became 
more similar. Correspondence is good although slightly less than perfect. 
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Figure  5.  Simulation  of  Milan  data  in  blue  and  actual  Milan  data  for  premenopausal 
patients  in  red.  Format  is  hazard  of  relapse.  We  are  comparing  the  Milan  data  for 
premenopausal patients and the simulation. We adjusted the simulation to try and agree 
with hazard for the Milan data. Time scale is 120 months. 
 
Figure  6.  Simulation  of  Milan  data  in  blue  and  actual  Milan  data  for  premenopausal 
patients in red. Format is disease free survival. 
 
4. Discussion—Analysis and Synthesis 
We two authors each have backgrounds in physics in addition to doing cancer research. Physicists 
have long considered analysis and synthesis to be a very useful strategy to help understand a complex 
item. By taking the item apart, examining the individual components and demonstrating how they 
work together by reassembling the pieces, the scientists demonstrate some new level of understanding.   
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That is precisely what we have done in this breast cancer study. We found two early and one late 
relapse modes. We have quantified their separate growths in a computer simulation and shown the 
temporal connection to the surgery event. We show in Figures 5 and 6 that the three relapse modes 
together  can  visually  resemble  clinical  data  from  the  Milan  database  and  also  agree  with 
Adjuvant-on-line specific clinical situations. 
Physicists also ascribe to the scientific method that starts by proposing a testable hypothesis to 
explain data. An important step here is to attempt to correlate this hypothesis with other observations 
that have not previously been connected. This has been done as we reported in Cancers in 2010 among 
which is the ability to explain why adjuvant chemotherapy works best by far for premenopausal node 
positive patients and also why early detection of breast cancer is more effective for women age 50–59 
years than it is for women age 40–49 years. We eagerly await the opportunity to prospectively confirm 
a key prediction that a perioperative NSAID can dramatically reduce early relapses at low cost and low 
toxicity. One such trial is scheduled to begin this year in Seoul, South Korea at the Samsung Medical 
Center. 
5. Conclusions 
We have verified that at least in this application a relatively small database consisting of good 
quality data is far more important than one of large size and questionable quality data. We compliment 
and thank Pinuccia Valagussa for developing and providing the Milan database upon which all this is 
based. 
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